Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus carboplatin and etoposide for previously untreated extensive-stage small-cell lung cancer with poor performance status
jRCTs031200319Phase 2Completed
- Sponsor
- North East Japan Study Group
- Start
- Apr 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, carboplatin and etoposide in small cell lung cancer (SCLC), sponsored by North East Japan Study Group. Primary endpoint: Tolerability of durvalumab, carboplatin and etoposide. Started Apr 2021; status: completed.
02
Drugs
durvalumabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCTs031200319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200319.